Printer Friendly

Chimp test for oral hepatitis B vaccine.

Chimp test for oral hepatitis B vaccine

Oral vaccination for hepatitis B has moved one step closer to human trials. Two years ago, virologists made a vaccine of viruses genetically engineered to carry parts of the hepatitis B virus (SN: 7/18/87, p.39) and showed it could immunize hamsters against the disease. Now, scientists at the same laboratory have successfully immunized chimpanzees, with their human-like immune systems, using a similar vaccine in a gelatin capsule.

An oral hepatitis B vaccine could cost less, hurt less and store better than the three-shot regimen of current vaccines for the disease. The virus, spread through blood and sexual contact, can cause liver diseases. It currently infects about 300 million people worldwide.

With their colleagues, Michael D. Lubeck of Wyeth-Ayerst Research in Philadelphia and Robert H. Purcell at the National Institute of Allergy and Infectious Diseases in Bethesda, Md., attached the major surface antigen of the hepatitis B virus to adenoviruses, which normally infect human lungs but can also grow in the gut. The team fed the still-viable viruses to three chimps.

The type 4 and 7 adenoviruses used in the study can cause acute respiratory disease if inhaled. But growing in the gut, they induce immunity rather than illness. The U.S. military has used oral vaccines to immunize millions of soldiers against adenovirus, achieving a safety record that makes adenoviruses good vaccine candidates, the researchers say.

Eight weeks after vaccination, the team experimentally infected all three vaccinated chimps and one unvaccinated control chimp with hepatitis B virus. Two chimps that developed some antibodies to hepatitis B virus successfully fought off infection. The third vaccinated chimp developed no antibodies and contracted the disease, as did the control chimp.

The study represents the first report of a virus-carried vaccine stimulating hepatitis B antibodies in chimps, says virologist Bernard N. Fields of Harvard University Medical School in Boston. Moreover, it demonstrates for the first time that chimps can be infected with adenoviruses 4 and 7, Purcell and his colleagues assert in the September PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (Vol.86, No.17). And because adenoviruses normally infect humans rather than chimps, Fields and Purcell say the vaccine might stimulate a stronger antibody response in people.

"This may be the last step before clinical trials because this also constitutes a safety test of the recombinant carrier in what I think is a relevant animal model system," Purcell says.
COPYRIGHT 1989 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1989, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Author:Hart, S.
Publication:Science News
Date:Sep 23, 1989
Words:406
Previous Article:Sizing up SADness according to latitude.
Next Article:Down payment for collider construction.
Topics:


Related Articles
Yeast-made vaccine nearing market.
AIDS vaccine: time for human tests?
Will there be an AIDS vaccine? Research is speeding ahead, but there are many scientific roadblocks in the way of developing a safe and effective...
Oral vaccine sought for hepatitis B.
Human test of AIDS vaccine approved.
AIDS vaccine: preliminary but promising.
Changing hepatitis C evades immune systems.
Vaccine shields chimps from HIV.
For research chimpanzees, a retirement home: aging chimps are getting a taxpayer-funded sanctuary. Some scientists worry it s a step toward getting...
Late failure of combined recombinant hepatitis B vaccine and lamivudine in treatment of a patient with chronic hepatitis B.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters